Skip to main content

CLARIFICATION: University of Washington Will Use Amersham Proteomics, Microarray Systems

This brief mistakenly reported that Amersham's 2-D gel system lets researchers compare as many as three proteins at a time. In fact, the system allows for simultaneous comparisons of up to three protein samples.

NEW YORK, March 11 - University of Washington researchers will use Amersham proteomics and mRNA expression systems in order to explore cell function, the two said today.


Amersham will provide the UW researchers with its 2-D Differential In-Gel Electrophoresis system and DNA microarray platform. Its 2-D gel system allows for simultaneous comparisons of up to three protein samples at a time.


The system will be located in the lab of Roger Bumgarner, director of UW's Center for Expression Arrays.


Bumgarner, who is a research scientist in the university's department of molecular biotechnology, is now working on a high throughput genotyping system that makes use of simple sequence repeat polymorphisms. He is also developing software to be used  for the analysis of differential hybridizations on high density DNA arrays.


Financial details of the Amersham deal were not disclosed.

The Scan

WHO OKs Emergency Use of Sinopharm Vaccine

The World Health Organization has granted emergency approval for Sinopharm's SARS-CoV-2 vaccine, the Guardian reports.

Scientific Integrity Panel to Meet

According to the Associated Press, a new US scientific integrity panel is to meet later this week.

Trying in the Eye

NPR reports that a study of Editas Medicine's CRISPR therapy for Leber congenital amaurosis has begun.

PLOS Papers on Cerebellum Epigenetics, Copy Number Signature Tool, Acute Lung Injury Networks

In PLOS this week: epigenetics analysis of brain tissue, bioinformatics tool to find copy number signatures in cancer, and more.